Publication date: May 08, 2024
Despite considerable progress in developing vaccines and antivirals to combat COVID-19, the rapid mutations of the SARS-CoV-2 genome have limited the durability and efficacy of the current vaccines and therapeutic interventions. Hence, it necessitates the development of novel therapeutic approaches or repurposing existing drugs that target either viral life cycle, host factors, or both. Here, we report that SRX3177, a potent triple-activity CDK4/6-PI3K-BET inhibitor, blocks replication of the SARS-CoV-2 Omicron variant with IC values at sub-micromolar concentrations without any impact on the cell proliferation of Calu-3 cells at and below its IC concentration. When SRX3177 is combined with EIDD-1931 (active moiety of a small-molecule prodrug Molnupiravir) or MU-UNMC-2 (a SARS-CoV-2 entry inhibitor) at a fixed doses matrix, a synergistic effect was observed, leading to the significant reduction in the dose of the individual compounds to achieve similar inhibition of SARS-CoV-2 replication. The study’s outcome indicates that the combination of SRX3177/MPV or SRX3177/UM-UNMC-2 has the potential for further development as a combinational therapy against SARS-CoV-2 and in any future outbreak of beta coronavirus.
| Concepts | Keywords |
|---|---|
| Cdk4 | Combinatorial |
| Host | Entry inhibitor |
| Srx3177 | RdRp inhibitor |
| Therapy | SRX3177 |
| Vaccines | Triple inhibitor |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| pathway | KEGG | Viral life cycle |
| disease | IDO | host |
| disease | VO | report |
| disease | IDO | replication |
| disease | VO | dose |